

Accepted Manuscript

Anomeric spirocycles by solvent incorporation: reactions of *O*-peracylated (glyculopyranose and glyculopyranosyl bromide)onamide derivatives with ketones

András Páhi, Katalin Czifrák, Katalin E. Kövér, László Somsák


PII: S0008-6215(14)00129-3
DOI: <http://dx.doi.org/10.1016/j.carres.2014.04.003>
Reference: CAR 6720

To appear in: *Carbohydrate Research*

Received Date: 13 March 2014
Revised Date: 31 March 2014
Accepted Date: 1 April 2014

Please cite this article as: Páhi, A., Czifrák, K., Kövér, K.E., Somsák, L., Anomeric spirocycles by solvent incorporation: reactions of *O*-peracylated (glyculopyranose and glyculopyranosyl bromide)onamide derivatives with ketones, *Carbohydrate Research* (2014), doi: <http://dx.doi.org/10.1016/j.carres.2014.04.003>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

**Anomeric spirocycles by solvent incorporation:
reactions of *O*-peracylated (glyculopyranose and glyculopyranosyl
bromide)onamide derivatives with ketones**

András Páhi,¹ Katalin Czifrák,¹ Katalin E. Kövér,² László Somsák^{1*}

¹*Department of Organic Chemistry,*

²*Department of Inorganic and Analytical Chemistry,*

University of Debrecen, ¹POB 20, ²POB 21, H-4010 Debrecen, Hungary

Abstract

Reactions of *O*-peracetylated (α -D-*galacto*-heptulopyranosyl bromide)onamide and *O*-perbenzoylated (α -D-*gluco*-heptulopyranosyl bromide)onamide with ketones in the presence of silver(I) salt promoters gave the corresponding *O*-peracylated 1',5'-anhydro-D-glycitol-spiro-[1',5]-4-imino-2,2-disubstituted-1,3-dioxolanes. The D-*galacto* configured starting compounds furnished both spiro epimers, while the D-*gluco* counterparts yielded only configurationally inverted products. Under acidic conditions, *O*-perbenzoylated α -D-*gluco*-heptulopyranosonamide and ketones yielded the protected 1',5'-anhydro-D-glucitol-spiro-[1',5]-2,2-disubstituted-oxazolidin-4-ones, which were *O*-debenzoylated by the Zemplén protocol. These compounds had no inhibition against rabbit muscle glycogen phosphorylase *b*.

Keywords

solvent incorporation; spiro compounds; anomeric spirocycles; 4-imino-1,3-dioxolanes; oxazolidin-4-ones

* Corresponding author – Tel.: +3652512900 ext. 22348, Fax: +3652512744, E-mail: somsak.laszlo@science.unideb.hu

1. Introduction

1
2
3
4
5 Spirocyclic motifs are widespread among natural products and synthetic compounds, and
6
7 often exhibit interesting and useful biological activities.¹⁻³ Spirocycles involving the anomeric
8
9 carbon of monosaccharide derivatives are also well known, and have been, among others,
10
11 shown to possess antiparasitic,⁴ antibacterial, antifungal,⁵ antidiabetic,⁶ herbicide,⁷
12
13 glycosidase⁸⁻¹⁰ and glycogen phosphorylase¹¹ inhibitory activities.

14
15
16
17 Synthetic strategies to obtain spirocycles were amply reviewed,¹⁻³ and ring closure of
18
19 geminally disubstituted cyclic compounds were highlighted as one of several generally
20
21 applied approaches towards various spiro derivatives. Following this principle for the
22
23 preparation of anomeric spirocycles the necessary starting compounds can be selected from
24
25 monosaccharides homo- or heterobifunctionalized at the anomeric centre.* The latter type
26
27 precursors are represented among others by derivatives of ulose type sugars utilized e. g. for
28
29 the syntheses of many sorts of spironucleosides.¹² In this line we reported the transformations
30
31 of (glyculopyranosyl bromide)onic acid derivatives¹³ to glycopyranosylidene-spiro-
32
33 (thio)hydantoin,^{14,15} -thiazolidinones,¹⁶ and -oxazolines,¹⁷ as well as that of
34
35 (glyculopyranosyl thiocyanate)onitriles to glycopyranosylidene-spiro-thiazolines.¹⁸

36
37
38
39 Some years ago we observed that on generation of the corresponding glycosylium ion
40
41 from (glyculopyranosyl bromide)onamides (e. g. **1**) by Ag₂CO₃ in acetone spiro-imino-
42
43 dioxolanes **2a** and **3a** (Table 1) were formed by incorporation of the solvent.¹⁹ This reaction
44
45 can be regarded as a direct *O*-glycosylation of a ketone which is a very rare transformation:
46
47 formation of acetal glycosides in the presence of ketones was described from *O*-peracetylated
48
49 *N*-(2,4-dinitrophenyl)- α -D-glucosaminyl bromide (but not from acetobromoglucose),²⁰ TMS-
50
51
52
53
54
55
56
57
58


59
60 * Strictly speaking these compounds might no more have a „real” anomeric i. e. an acetal type carbon in many
61 cases, however, for the sake of simplicity this term will be used here.

glycosides,^{21,22} and *O*-perbenzylated 1-thioglycosides.²³ Formal glycosylation of ketones by a special intramolecular aglycon delivery was recently reported.²⁴

In this paper full experimental details are reported for the extension of the above ketone incorporation in reactions of (glyculopyranosyl bromide)onamides. Furthermore, studies on the reactions of (glyculopyranose)onamides and ketones as well as detailed structural elucidation of the compounds are also described.

2. Results and Discussion

Following the first observation¹⁹ on incorporation of acetone into the products in the reaction of **1** (Table 1, Entry 1) in the presence of Ag₂CO₃, the applicability of other ketones and promoters were investigated. With butanone both Ag₂CO₃ and AgOTf gave similar results (Entries 2 and 3) expectedly furnishing the spiro-dioxolanes **2b** and **3b** as inseparable diastereomeric mixtures. Symmetrical ketones (Entries 4-6) also gave the spiro-epimers **2c-e** as the main products whereby **3c-e** could be isolated in much lower yields. From each reaction mixture the hydrolytic product **4** could be isolated in 25-38 % yields.

Table 2. Reaction of *O*-perbenzoylated (α -D-*gluco*-heptulopyranosyl bromide)onamide (**5**) with ketones

| Entry | R ¹ | R ² | Promoter | R. time | Yield (%) | | |
|-------|----------------|------------------------------------|----------|---------------------------------|-----------|----|----|
| 1. | a | Me | Me | Ag ₂ CO ₃ | 11 d | 17 | 41 |
| 2. | | | | AgOTf | 1 d | 37 | 46 |
| 3. | c | Et | Et | Ag ₂ CO ₃ | 20 d | 5 | 34 |
| 4. | | | | AgOTf | 1 d | 46 | 35 |
| 5. | d | -(CH ₂) ₄ - | | Ag ₂ CO ₃ | 13 d | 56 | 18 |
| 6. | e | -(CH ₂) ₅ - | | AgOTf | 1 d | 28 | 35 |


Attempts to reduce the amount of the ketones to 5-10 equivalents in nitromethane as the solvent proved unsuccessful, and the only products to be observed were **4** and **7**. Trials to use aldehydes as the carbonyl reagents resulted in multicomponent mixtures from which no discrete products could be isolated.

Reactions of (D-*gluco*-hept-2-ulopyranose)onamide **7** with ketones were investigated next (Table 3). As in similar cyclizations of non-carbohydrate α -hydroxy-carboxamides *p*-toluenesulfonic acid (*p*TSA) was frequently applied to promote the transformation²⁵ this acid was tried first. However, no reaction of **7** could be observed with acetone as the solvent in the presence of either catalytic or stoichiometric amounts of *p*TSA. On the other hand, catalytic triflic acid (TfOH) elicited the reaction (Entry 1), and raising its amount to one equivalent significantly increased the yield of **8a** (Entry 2). Under the same conditions butanone gave an inseparable diastereomeric mixture of **8b** (Entry 3). The amount of the ketone could be diminished to 5 equivalents, and both THF and toluene proved suitable solvents to prepare **8c**-

f in good yields (Entries 4-7). In these reactions formation of one compound was observed in each case (disregarding diastereomers **8b**). Reactions with aldehydes gave only decomposition products.

Spiro-oxazolidinones **8** were *O*-debenzoylated by the Zempén protocol to give compounds **9** in very good yields. These derivatives were tested as possible inhibitors of rabbit muscle glycogen phosphorylase *b*, however, showed no inhibition up to 625 μM concentration.

Table 3. Reaction of 3,4,5,7-tetra-*O*-benzoyl- α -D-*gluco*-heptulopyranosamide (**5**) with ketones



| Entry | R ¹ | R ² | Ketone equiv. | Solvent | Acid equiv. | Yield (%) | | |
|-------|----------------|------------------------------------|---------------|------------|-------------|-----------|-----------------|----|
| 1. | a | Me | Me | as solvent | - | 0.1 | 58 | 94 |
| 2. | | | | as solvent | - | 1.0 | 89 | |
| 3. | b | Me | Et | as solvent | - | 1.0 | 92 ^a | 96 |
| 4. | | | | 5 | THF | 1.0 | 69 | |
| 5. | d | Et | Et | 5 | THF | 1.0 | 86 | 91 |
| 6. | e | -(CH ₂) ₄ - | 5 | THF | 1.0 | 86 | 91 | 91 |
| 7. | e | -(CH ₂) ₅ - | 5 | toluene | 1.0 | 69 | 91 | 96 |
| 8. | f | -(CH ₂) ₆ - | 5 | toluene | 1.0 | 71 | 91 | 77 |

^aTwo diastereomers.

Structural elucidation of the products (following the mass spectrometric determination of the molecular masses) was carried out by NMR methods as illustrated for the compounds depicted in Figure 1 (see also Table 4 for selected NMR data of the compounds). Proton spectra showed splitted resonances for a pyranoid ring in the ⁴C₁ conformation as well as the

1 expected signals of the aliphatic parts and the presence of an exchangeable proton assigned as
2 an NH for each compound (see details in the Experimental section). The carbon spectra
3
4 contained (besides the expected resonances for the sugar ring, the acyl protecting groups and
5 the aliphatic moieties) signals for three carbons with no attached hydrogens. Those in the
6
7 range of 99.9-100.7 ppm were assigned as the C-[1',5] spiro centres. Resonances of 112.5-
8
9 122.2 and 158.2-160.9 ppm (clearly distinct from the C=O resonances of the protective
10
11 groups) were indicative of acetal and imidate type carbons, respectively, in compounds **2**, **3**,
12
13 and **6**. On the contrary, the spectra of compounds **8** exhibited an additional signal in the range
14
15 of the benzoyl carbonyls (162.4-166.6 ppm) and from these that of the highest chemical shift
16
17 was (tentatively) assigned to amide C-4. A resonance in the range of 92.4-100.1 ppm could be
18
19 attributed to an aminor type carbon and this corroborated that the nitrogen was in an
20
21 endocyclic position in **8**. To confirm the difference in the constitution of the heterocyclic parts
22
23 of the spirocycles, CPMG-HSQMBC experiments²⁶⁻²⁸ were carried out with **6a** and **8e**. In
24
25 these spectra cross peaks (indicated by asterisks in the formulae of the respective compounds
26
27 in Fig. 1) between NH and C-4 and C-5, but not with C-2, were observed for **6a** to further
28
29 prove the imino-dioxolane structure. On the other hand, cross peaks between NH and C-2, C-
30
31 4, and C-5, as well as with carbons of the aliphatic substituent were present for **8e** to verify
32
33 the oxazolidinone ring. For **8e** this measurement also corroborated the chemical shift
34
35 assignment of amide C-4. The configuration of the spiro carbons C-[1',5] was established as
36
37 *R* for **2** and **6**, and *S* for **3** and **8** based on the three bond heteronuclear coupling constants
38
39 between H-2 and C-4 shown in Fig. 1 indicating the *trans* diaxial vs. *gauche* relationships
40
41 between the respective nuclei in the ⁴C₁ conformation of the sugar ring. Although these
42
43 couplings could not be measured for each compound due to insufficient sample quantities, no
44
45 doubt was left about the spiro configuration of the other members of the series. Namely, the
46
47 proton resonances had characteristic shifts depending on the C-[1',5] configuration (cf. Fig. 1
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

and Table 4): H-2' had a downfield shift of ~0.1-0.2 ppm if the C=NH/C=O was on the same side of the pyranoid ring; similarly, downfield shifts were observed for H-3' (~0.7 ppm) and H-5' (~0.4 ppm) when they were in the same situation. Analogous ^1H chemical shift patterns were observed earlier for other glycopyranosylidene-spiro-heterocycles.^{14,15}








Figure 1. Representative NMR data for the structural elucidation of the new compounds.

Table 4. Selected NMR data for the *O*-peracylated compounds^a **2**, **3**, **6**, and **8** (δ [ppm], J [Hz])

| | 2a^b | 2b | 2c | 2d | 2e |
|---|-------------------------|-------------------------|-----------|-------------------------|-------------------------|
|  | | | | | |
| H-2' | 5.58 | 5.54/5.59 | 5.60 | 5.57 | 5.57 |
| H-3' | 6.00 | 6.05/5.89 | 5.99 | 5.98 | 6.01 |
| H-5' | 4.88 | 4.75/4.85 | 4.85 | 4.84 | 4.85 |
| C-[1',5] | 100.4 | 100.2/100.3 | 99.9 | 100.1 | 100.1 |
| C-2 | 112.6 | 114.7/114.1 | 116.8 | 116.2 | 113.2 |
| C-4 | 160.9 | 160.4/160.2 | 160.4 | 158.8 | 158.2 |
| ³ J _{H-2',C-4} | 5.6 | 4.1 | 6.1 | 6.1 | 5.3 |
|  | | | | | |
| H-2' | 5.74 | 5.74/5.69 | 5.74 | 5.75 | 5.75 |
| H-3' | 5.25 | 5.35/5.20 | 5.30 | 5.26 | 5.26 |
| H-5' | 4.41 | 4.43/4.39 | 4.42 | 4.41 | 4.41 |
| C-[1',5] | 100.3 | 100.9/100.9 | 100.8 | 100.8 | 100.8 |
| C-2 | 112.5 | 114.8/113.8 | 116.2 | 113.1 | 113.1 |
| C-4 | 161.2 | 160.2/160.2 | 160.8 | 160.3 | 160.3 |
| ³ J _{H-2',C-4} | <i>n.m.^c</i> | <i>n.m.^c</i> | 2.1 | <i>n.m.^c</i> | <i>n.m.^c</i> |
|  | | | | | |
| H-2' | 5.85 | 5.92 | 5.87 | 5.87 | 5.87 |
| H-3' | 6.80 | 6.82 | 6.82 | 6.82 | 6.82 |
| H-5' | 5.13 | 5.13 | 5.12 | 5.14 | 5.14 |
| C-[1',5] | 100.3 | 99.9 | 99.9 | 99.8 | 99.8 |
| C-2 | 112.8 | 116.6 | 122.2 | 113.5 | 113.5 |
| C-4 | 160.5 | 160.6 | 160.3 | 160.4 | 160.4 |
| ³ J _{H-2',C-4} | 5.4 | 4.9 | 4.9 | 5.0 | 5.0 |



| | 8a | 8b | 8c | 8d | 8e | 8f |
|------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-----------|--------------------------|
| H-2' | 5.96 | 5.99/5.97 | 6.00 | 5.97 | 6.00 | 5.98 |
| H-3' | 6.09 | 6.10/6.09 | 6.10 | 6.08 | 6.10 | 6.08 |
| H-5' | 4.66 | 4.63/4.63 | 4.64 | 4.63 | 4.69 | 4.66 |
| H-4' | 5.73 | 5.72/5.71 | 5.70 | 5.73 | 5.71 | 5.70 |
| C-[1',5] | 100.5 | 100.3/100.35 | 100.2 | 100.7 | 100.1 | 100.1 |
| C-2 | 92.4 | 94.9, 94.5 | 97.1 | 100.1 | 93.5 | 97.2 |
| C-4 | 166.0 | 166.4/166.1 | 166.6 | 166.1 | 166.4 | 166.1 |
| ³ J _{H-2',C-4} | <i>n.m.</i> ^c | <i>n.m.</i> ^c | <i>n.m.</i> ^c | <i>n.m.</i> ^c | 2.5 | <i>n.m.</i> ^c |


^aFor substituents R¹ and R² see the respective Tables (Table 1 for **2** and **3**, Table 2 for **6**, and Table 3 for **8**).

^bData taken from ref.¹⁹ ^cNot measured because of insufficient sample quantity.

Formation of spirocycles **2**, **3**, and **6** can be understood by following the mechanistic proposal in Scheme 1. The silver salt promoter facilitates the generation of the corresponding glycosylium ion **B1** from **1** or **5**. Nucleophilic attack of a ketone with anchimeric assistance of the 2-*O*-acyl group (**D1**) may lead to carbocation **A1** while without neighbouring group participation the epimeric cation, represented by resonance forms **E1** and **F1**, can be formed. Intramolecular attack of the amide oxygen (illustrated in details for **F1** only), the harder part of this functional group, may give the cyclized iminium ion **C1**. Deprotonation of this intermediate and that of the analogous one (not shown) derived from **A1** give then the isolated products of retained (**3**) and inverted configuration (**2**), respectively. Formation of the by-products **4** and **7** are to be explained by the water content of the solvents attacking on glycosylium ion **B1**. The finding that from the *D-gluco* configured **5** only the formation of **6** was observed,^{*} while **1** of the *D-galacto* configuration gave both epimers **2** and **3**, may be

* It is to be noted that from the acetylated counterpart of **5** formation of a very minor amount (6 %) of the inverted product was reported.¹⁹

indicative of a remote participation²⁹ of the axial 4-*O*-acetyl group of **1** facilitating the formation of **3**.




Scheme 1. Proposed mechanism for the formation of 1',5'-anhydro-D-glycitol-spiro-[1',5]-4-imino-1,3-dioxolanes **2**, **3**, and **6**.

A mechanistic proposal for the formation of spirocycles **8** (Scheme 2) can be more complex since, due to the presence of several functional groups whose protonation may start the reaction, alternative pathways may occur simultaneously. The first (most tempting) possibility is the protonation of the glycosidic OH in **7** followed by loss of water to give glycosylium **C2** which is the same intermediate as **B1** in Scheme 1. Attack of a ketone on **C2** would give **A2** (equal to intermediate **F1** in Scheme 1), however, the formation of the epimeric intermediate **A1** (shown in Scheme 1) must also be taken into account. This

possibility renders this pathway less probable since only the configurationally retained epimer **8** was observed in the reactions. Formation of **A2** (without epimerization) should also be possible via protonation and subsequent dehydration of a mixed hemiketal **E2** which can develop from **7** by nucleophilic addition of the glycosidic OH to the ketone or its protonated form **D2**. Ring closure of **A2** (= **F1**) occurred by the nucleophilic attack of the amide oxygen under conditions of Scheme 1 (cf **F1**→**C1**) to give the imino-dioxolanes **3**, however, these compounds were not present in the reactions of **7** (Scheme 2). Considering the different reaction conditions this may raise two possibilities: i) imino-dioxolanes may be formed as primary products which then give oxazolidinones **8** in a proton catalysed equilibration; ii) ring closure takes place by a N-nucleophilic attack of the hydroximide tautomer of the amide moiety. The first possibility was ruled out by an experiment in which an imino-dioxolane **6** was subjected to the conditions of the formation of **8**. Thus, **6a** was boiled in acetone in the presence of TfOH (1 equiv) for 24 h, however, no change could be detected by TLC. The second possibility can be reasonable since tautomerisation of amides under acidic conditions (cf **7**→**F2**→**I2**) is a known phenomenon.³⁰ Thus, **A2** may ring-close to protonated hydroxy-oxazoline **B2** which, after deprotonation and tautomerization can give the isolated **8**.

Since α -hydroxy-carboxamides and carbonyl compounds are known to furnish oxazoles under acidic conditions, the generally accepted mechanism of the Fischer oxazole synthesis²⁵ should also be considered in the present transformation. Protonation of the amide oxygen of **7** as shown in **F2** may result in a tautomerisation³⁰ to give at least a minor proportion of **I2** which can attack the ketone (or its protonated form **D2**) as a N-nucleophile to give intermediate **J2**. Protonation of a hydroxyl group in **J2** may lead to elimination of water to produce either carbocation **G2** or **K2**, both of which can ring close to **H2** by the nucleophilic attack of the remaining OH on the positively charged carbon. Due to the presence of three electron releasing substituents, carbocation **K2** might be more stable than glycosyliumion **G2**,

therefore, formation of **H2** via **K2** might be preferred. This is also made likely by the formation of a single isomer of **8** that would probably not be the case in route **J2**→**G2**→**H2**. Final deprotonation and tautomerisation of **H2** may then yield the isolable product **8**.



Scheme 2. Possible mechanistic pathways for the formation of 1',5'-anhydro-D-glucitol-spiro-[1',5]-oxazolidin-4-ones **8**.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

In conclusion, the reactions of (glyculopyranose and glyculopyranosyl bromide)onamides with ketones gave access to the preparation of new anomeric spirocycles, namely, 1',5'-anhydro-D-glycitol-spiro-[1',5]-4-imino-2,2-disubstituted-dioxolanes and 1',5'-anhydro-D-glycitol-spiro-[1',5]-2,2-disubstituted-oxazolidin-4-ones. The structures were unambiguously assigned by NMR methods. Detailed mechanisms were proposed to explain the formation of both constitutional isomers as well as the stereoselectivities of the ring forming reactions. The spiro-oxazolidinones were tested against rabbit muscle glycogen phosphorylase *b*, however, had no inhibitory effect.

3. Experimental

3.1. General methods

Melting points were measured in open capillary tubes or on a Kofler hot-stage and are uncorrected. Optical rotations were determined with a Perkin-Elmer 241 polarimeter at room temperature. NMR spectra were recorded with Bruker 200 (200/50 MHz for $^1\text{H}/^{13}\text{C}$), Bruker DRX 360 (360/90 MHz for $^1\text{H}/^{13}\text{C}$) or Avance II 500 (500/125 MHz for $^1\text{H}/^{13}\text{C}$) spectrometers. Chemical shifts are referenced to Me_4Si (^1H), or to the solvent signals or DSS in D_2O (^{13}C). Mass spectra were recorded by a Bruker micrOTOF-Q instrument. TLC was performed on DC-Alurolle Kieselgel 60 F_{254} (Merck), and the plates were visualised under UV light and by gentle heating. For column chromatography Kieselgel 60 (Merck, particle size 0.063-0.200 mm) was used. Dichloromethane was distilled from P_4O_{10} and acetone from CaSO_4 and stored over 4Å molecular sieves. Organic solutions were dried over anhydrous MgSO_4 and concentrated under diminished pressure at 40-50 °C (water bath).

3.2. General procedure I for the preparation of *O*-peracylated 1',5'-anhydro-D-glycitol-spiro-[1',5]-4-imino-2,2-disubstituted-1,3-dioxolanes **2**, **3**, and **6**

To a solution of an *O*-peracylated (glyculopyranosyl bromide)onamide **1**³¹ or **5**³² (0.50 g) in a dry ketone (5 mL) containing molecular sieves (3 Å) Ag₂CO₃ (1 equiv) or AgOTf/Et₃N (1 equiv) were added. The mixture was stirred at rt in the dark under Ar atmosphere until TLC (1:1 or 1:2 EtOAc-hexane) showed complete transformation of the starting material. Then the mixture was filtered on a Celite pad and the solvent removed under diminished pressure. The crude product was purified by column chromatography.

3.2.1. (1'*R*,2*RS*)- and (1'*S*,2*RS*)-2',3',4',6'-Tetra-*O*-acetyl-1',5'-anhydro-D-galactitol-spiro-[1',5]-2-ethyl-4-imino-2-methyl-1,3-dioxolanes (**2b** and **3b**)

Prepared from **1** (0.50 g, 1.10 mmol) and butanone in the presence of AgOTf according to General procedure I (section 3.2). Column chromatography (1:1 EtOAc-hexane) gave three fractions.

Fraction I: 0.21 g (43%) of an inseparable diastereomeric mixture of **2b** as a colourless oil; *R*_f = 0.71 (1:1 EtOAc-hexane).

Characterisation of diastereomer A: ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 7.40 (s, 1H, NH), 6.05 (dd, 1H, *J*_{2',3'} 11.1 Hz, *J*_{3',4'} 3.2 Hz, H-3'), 5.54 (d, 1H, *J*_{2',3'} 11.1 Hz, H-2'), 5.51 (dd, 1H, *J*_{3',4'} 3.2 Hz, *J*_{4',5'} 1.0 Hz, H-4'), 4.75 (ddd, 1H, *J*_{5',6'a} 6.8 Hz, *J*_{5',6'b} 6.3 Hz, *J*_{4',5'} 1.0 Hz, H-5'), 4.20-4.02 (m, 2H, H-6'a, H-6'b), 2.15, 2.05, 1.95, 1.93 (4s, 12H, OCOCH₃), 1.70 (q, 2H, *J* 7.3 Hz, CH₂CH₃), 1.35 (s, 3H, CH₃), 0.88 (t, 3H, *J* 7.3 Hz, CH₂CH₃); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 170.3, 170.0, 169.6, 169.3 (CO), 160.4 (C-4, ³*J*_{H-2',C-4} = ~4.1 Hz), 114.7 (C-2),

100.2 (C-1'), 69.8, 68.8, 67.5, 66.9 (C-2' - C-5'), 61.3 (C-6'), 33.4 (CH₂CH₃), 25.6 (CH₃),
20.7, 20.5, 20.3, 20.2 (COCH₃); 6.9 (CH₂CH₃).

Characterisation of diastereomer B: ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 7.40 (s, 1H, NH),
5.89 (dd, 1H, *J*_{2',3'} 11.1 Hz, *J*_{3',4'} 3.2 Hz, H-3'), 5.59 (1H, d, *J*_{2',3'} 11.1 Hz, H-2'), 5.48 (dd, 1H,
*J*_{3',4'} 3.2 Hz, *J*_{4',5'} 1.0 Hz, H-4'), 4.85 (ddd, 1H, *J*_{5',6'a} 6.8 Hz, *J*_{5',6'b} 6.3 Hz, *J*_{4',5'} 1.0 Hz, H-5'),
4.20-4.02 (m, 2H, H-6'a, H-6'b), 2.16, 2.04, 1.98, 1.94 (4s, 12H, OCOCH₃), 1.85 (q, 2H, *J*
7.3 Hz, CH₂CH₃), 1.55 (s, 3H, CH₃), 0.96 (t, 3H, *J* 7.3 Hz, CH₂CH₃); ¹³C NMR (CDCl₃, 90
MHz): δ (ppm) 170.2, 170.0, 169.8, 169.1 (CO), 160.2 (C-4), 114.1 (C-2), 100.3 (C-1'), 69.9,
68.8, 67.2 (2) (C-2' - C-5'), 61.3 (C-6'), 32.4 (CH₂CH₃), 25.6 (CH₃), 20.8, 20.5, 20.3, 20.1
(OCOCH₃), 6.9 (CH₂CH₃). Calcd for C₁₉H₂₇NO₁₁ (Mol. Wt.: 445.42, Ex. Mass.: 445.16);
ESI-MS (positive mode) *m/z*: 468.148 [M+Na]⁺, 913.305 [2M+Na]⁺.

Fraction II: 0.10 g (19%) of an inseparable diastereomeric mixture of **3b** as a yellowish oil; *R*_f
= 0.36 (1:1 EtOAc-hexane).

Characterisation of diastereomer C: ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 7.48 (s, 1H, NH),
5.74 (d, 1H, *J*_{2',3'} 11.1 Hz, H-2'), 5.51 (dd, 1H, *J*_{3',4'} 3.2 Hz, *J*_{4',5'} 1.0 Hz, H-4'), 5.35 (dd, 1H,
*J*_{2',3'} 11.1 Hz, *J*_{3',4'} 3.2 Hz, H-3'), 4.43 (ddd, 1H, *J*_{5',6'a} 6.8, *J*_{5',6'b} 6.3 Hz, *J*_{4',5'} 1.0 Hz, H-5'),
4.20-4.03 (m, 2H, H-6'a, H-6'b), 2.10, 2.08, 2.01, 1.98 (4s, 12H, OCOCH₃), 1.88 (q, 2H, *J*
7.3 Hz, CH₂CH₃), 1.54 (s, 3H, CH₃), 1.00 (t, 3H, *J* 7.3 Hz, CH₂CH₃); ¹³C NMR (CDCl₃, 90
MHz): δ (ppm) 170.4, 170.2, 169.8, 169.1 (CO), 160.2 (C-4), 114.8 (C-2), 100.9 (C-1'), 69.7,
68.6, 67.7, 66.5 (C-2' - C-5'), 61.7 (C-6'), 32.4 (CH₂CH₃), 25.8 (CH₃), 20.7, 20.5, 20.2, 20.1
(COCH₃); 6.8 (CH₂CH₃).

Characterisation of diastereomer D: ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 7.48 (s, 1H, NH),
5.69 (d, 1H, *J*_{2',3'} 11.1 Hz, H-2'), 5.49 (dd, 1H, *J*_{3',4'} 3.2 Hz, *J*_{4',5'} 1.0 Hz, H-4'), 5.20 (dd, 1H,
*J*_{2',3'} 11.1 Hz, *J*_{3',4'} 3.2 Hz, H-3'), 4.39 (ddd, 1H, *J*_{5',6'a} 6.8 Hz, *J*_{5',6'b} 6.3 Hz, *J*_{4',5'} 1.0 Hz, H-
5'), 4.18-4.02 (m, 2H, H-6'a, H-6'b), 2.11, 2.09, 1.99, 1.97 (4s, 12H, OCOCH₃), 1.86 (2H, q,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

J 7.3 Hz, CH_2CH_3), 1.61 (s, 3H, CH_3), 1.26 (t, 3H, J 7.3 Hz, CH_2CH_3); ^{13}C NMR (CDCl_3 , 90 MHz) δ (ppm): 170.4, 170.0, 169.9, 169.6 (CO), 160.2 (C-4), 113.8 (C-2), 100.9 (C-1'), 69.7, 67.6, 66.2 (2) (C-2' - C-5'), 60.3 (C-6'), 33.5 (CH_2CH_3), 24.2 (CH_3), 20.7, 20.6, 20.2, 20.1 (COCH₃); 7.9 (CH_2CH_3). Calcd for $\text{C}_{19}\text{H}_{27}\text{NO}_{11}$ (Mol. Wt.: 445.42, Ex. Mass.: 445.16); ESI-MS (positive mode) m/z : 468.147 $[\text{M}+\text{Na}]^+$, 913.304 $[2\text{M}+\text{Na}]^+$.

Fraction III: 0.16 g (38%) of **4**¹⁴ as a white solid.

3.2.2. (1'R)- and (1'S)-2',3',4',6'-Tetra-O-acetyl-1',5'-anhydro-D-galactitol-spiro-[1',5]-2,2-diethyl-4-imino-1,3-dioxolanes (2c and 3c)

Prepared from **1** (0.50 g, 1.10 mmol) and pentan-3-one with AgOTf according to General procedure I (section 3.2). Column chromatography (1:1 EtOAc-hexane) gave three fractions.

Fraction I: 0.16 g (32 %) of **2c** as white crystals; mp: 100-102 °C; $[\alpha]_{\text{D}} +37$ (c 0.90, CHCl_3); ^1H NMR (CDCl_3 , 360 MHz): δ (ppm) 7.45 (s, 1H, NH), 5.99 (dd, 1H, $J_{2',3'}$ 11.1 Hz, $J_{3',4'}$ 3.7 Hz, H-3'), 5.60 (d, 1H, $J_{2',3'}$ 11.1 Hz, H-2'), 5.50 (dd, 1H, $J_{3',4'}$ 3.7 Hz, $J_{4',5'}$ 1.2 Hz, H-4'), 4.85 (ddd, 1H, $J_{5',6'a}$ 6.8 Hz, $J_{5',6'b}$ 6.3 Hz, $J_{4',5'}$ 1.2 Hz, H-5'), 4.17 (dd, 1H, $J_{6'a,6'b}$ 11.6 Hz, $J_{5',6'a}$ 6.8 Hz, H-6'a), 4.09 (dd, 1H, $J_{6'a,6'b}$ 11.6 Hz, $J_{5',6'b}$ 6.3 Hz, H-6'b), 2.17, 2.06, 2.02, 1.96 (4s, 12H, OCOCH₃), 1.87 (q, 2H, J 7.3 Hz, CH_2CH_3), 1.72 (q, 2H, J 7.3 Hz, CH_2CH_3), 0.96 (t, 3H, J 7.3 Hz, CH_2CH_3), 0.88 (t, 3H, J 7.3 Hz, CH_2CH_3); ^{13}C NMR (CDCl_3 , 90 MHz): δ (ppm) 170.1 (2), 169.6, 169.2 (CO), 160.4 (C-4, $^3J_{\text{H-2'},\text{C-4}} \approx -6.1$ Hz from HSQMBC at 125 MHz), 116.8 (C-2), 99.9 (C-1'), 69.7, 68.9, 67.3 (2) (C-2' - C-5'), 61.3 (C-6'), 31.2, 29.4 (CH_2CH_3), 20.5, 20.4 (2), 20.2 (COCH₃); 7.8, 6.7 (CH_2CH_3).

Fraction II: 0.07 g (14%) of **3c** as a white crystals, mp: 61-63 °C; $[\alpha]_{\text{D}} +59$ (c 1.00, CHCl_3);

^1H NMR (CDCl_3 , 360 MHz): δ (ppm) 7.42 (s, 1H, NH), 5.74 (d, 1H, $J_{2',3'}$ 11.1 Hz, H-2'), 5.51 (dd, 1H, $J_{3',4'}$ 3.2 Hz, $J_{4',5'}$ 1.1 Hz, H-4'), 5.30 (dd, 1H, $J_{2',3'}$ 11.1 Hz, $J_{3',4'}$ 3.2 Hz, H-3'),

4.42 (ddd, 1H, $J_{5',6'a}$ 6.8 Hz, $J_{5',6'b}$ 6.3 Hz, $J_{4',5'}$ 1.1 Hz, H-5'), 4.16 (dd, 1H, $J_{6'a,6'b}$ 11.6 Hz, $J_{5',6'a}$ 6.8 Hz, H-6'a), 4.11 (dd, 1H, $J_{6'a,6'b}$ 11.6 Hz, $J_{5',6'b}$ 6.3 Hz, H-6'b), 2.19, 2.03, 2.01, 1.98 (4s, 12H, OCOCH₃), 1.88 (q, 2H, J 7.3 Hz, CH₂CH₃), 1.84 (q, 2H, J 7.3 Hz, CH₂CH₃), 0.99 (t, 3H, J 7.3 Hz, CH₂CH₃), 0.95 (t, 3H, J 7.3 Hz, CH₂CH₃); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 170.3 (2), 170.1, 168.6 (CO), 160.8 (C-4, $^3J_{H-2',C-4}$ = ~2.1 Hz from HSQMBBC at 125 MHz), 116.2 (C-2), 100.8 (C-1'), 69.6, 69.2, 67.7, 66.1 (C-2' - C-5'), 61.8 (C-6'), 31.6, 29.0 (CH₂CH₃), 20.8, 20.5, 20.3 (2) (COCH₃); 8.0, 6.6 (CH₂CH₃); Calcd for C₂₀H₂₉NO₁₁ (Mol. Wt.: 459.44, Ex. Mass.: 459.17); ESI-MS (positive mode) m/z: 482.163 [M+Na]⁺, 941.337 [2M+Na]⁺.

Fraction III: 0.12 g (27%) of **4**¹⁴ as a white solid.

3.2.3. (1'R)- and (1'S)-2',3',4',6'-Tetra-O-acetyl-1',5'-anhydro-D-galactitol-spiro-[1',5]-4-imino-1,3-dioxolane-spiro-[2,1'']-cyclopentanes (**2d** and **3d**)

Prepared from **1** (0.20 g, 0.44 mmol) and cyclopentanone with AgOTf according to General procedure I (section 3.2). Column chromatography (1:1 EtOAc-hexane) gave three fractions.

Fraction I: 0.10 g (48%) of **2d** as white crystals; mp: 148-150 °C; [α]_D +28 (c 0.20, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 7.40 (s, 1H, NH), 5.98 (dd, 1H, $J_{2',3'}$ 11.1 Hz, $J_{3',4'}$ 3.6 Hz, H-3'), 5.57 (d, 1H, $J_{2',3'}$ 11.1 Hz, H-2'), 5.50 (dd, 1H, $J_{3',4'}$ 3.6 Hz, $J_{4',5'}$ 1.1 Hz, H-4'), 4.85 (ddd, 1H, $J_{5',6'a}$ 6.8 Hz, $J_{5',6'b}$ 6.3 Hz, $J_{4',5'}$ 1.1 Hz, H-5'), 4.15 (dd, 1H, $J_{6'a,6'b}$ 11.6 Hz, $J_{5',6'a}$ 6.8 Hz, H-6'a) 4.09 (dd, 1H, $J_{6'a,6'b}$ 11.6 Hz, $J_{5',6'b}$ 6.3 Hz, H-6'b), 2.16, 2.05, 2.03, 1.97 (4s, 12H, OCOCH₃), 1.92-1.84 (m, 4H, 2 × CH₂), 1.82-1.68 (m, 4H, 2 × CH₂); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm): 170.0 (2), 169.6, 169.0 (CO), 158.8 (C-4, $^3J_{H-2',C-4}$ = ~6.1 Hz), 116.2 (C-2), 100.1 (C-1'), 69.9, 68.6, 67.3, 67.2 (C-2' - C-5'), 61.2 (C-6'), 38.2, 36.6, 23.6,

22.6 (4 × CH₂), 20.6, 20.5 (2), 20.4 (COCH₃); Calcd for C₂₀H₂₇NO₁₁ (Mol. Wt.: 457.43, Ex.

Mass.: 457.16); ESI-MS (positive mode) m/z: 480.149 [M+Na]⁺, 937.306 [2M+Na]⁺.

Fraction II: traces of **3d** insufficient for NMR characterization. Calcd for C₂₀H₂₇NO₁₁ (Mol.

Wt.: 457.43, Ex. Mass.: 457.16); ESI-MS (positive mode) m/z: 480.147 [M+Na]⁺, 937.306 [2M+Na]⁺.

Fraction III: 0.045 g (26%) of **4**¹⁴ as a white solid.

3.2.4. (1'*R*)- and (1'*S*)-2',3',4',6'-Tetra-*O*-acetyl-1',5'-anhydro-D-galactitol-spiro-[1',5]-4-imino-1,3-dioxolane-spiro-[2,1]-cyclohexanes (**2e** and **3e**)

Prepared from **1** (0.50 g, 1.10 mmol) and cyclohexane with AgOTf according to General procedure I (section 3.2). Column chromatography (1:1 EtOAc-hexane) gave three fractions.

Fraction I: 0.23 g (44%) of **2e** as white crystals; mp: 124-126 °C; [α]_D +14 (c 0.22, CHCl₃);

¹H NMR (CDCl₃, 360 MHz): δ (ppm) 7.40 (s, 1H, NH), 6.01 (dd, 1H, *J*_{2',3'} 10.5 Hz, *J*_{3',4'} 3.2

Hz, H-3'), 5.57 (d, 1H, *J*_{2',3'} 10.5 Hz, H-2'), 5.51 (dd, 1H, *J*_{3',4'} 3.2 Hz, *J*_{4',5'} 1.0 Hz, H-4'),

4.85 (ddd, 1H, *J*_{5',6'a} 7.3 Hz, *J*_{5',6'b} 6.3 Hz, *J*_{4',5'} 1.0 Hz, H-5'), 4.10-4.08 (m, 2H, H-6'a, H-

6'b), 2.18, 2.08, 2.04, 1.97 (4s, 12H, OCOCH₃), 1.87-1.81 (m, 2H, CH₂), 1.77-1.56 (m, 4H, 2

× CH₂), 1.53-1.33 (m, 2H, CH₂), 1.30-1.23 (m, 2H, CH₂); ¹³C NMR (CDCl₃, 90 MHz): δ

(ppm) 170.8 (2), 169.2, 169.8 (CO), 158.2 (C-4, ³*J*_{H-2',C-4} = ~5.3 Hz), 113.2 (C-2), 100.1 (C-

1'), 69.9, 68.9, 67.5 (2) (C-2' - C-5'), 61.3 (C-6'), 37.2, 36.4, 24.4, 23.1 (2) (5 × CH₂), 20.8,

20.6 (2), 20.3 (COCH₃); Calcd for C₂₁H₂₉NO₁₁ (Mol. Wt.: 471.46, Ex. Mass.: 471.17); ESI-

MS (positive mode) m/z: 494.164 [M+Na]⁺, 965.339 [2M+Na]⁺.

Fraction II: 0.04 g (8 %) of **3e** as white crystals; mp: 112-114 °C; [α]_D +23 (c 0.20, CHCl₃);

¹H NMR (CDCl₃, 360 MHz): δ (ppm) 7.40 (s, 1H, NH), 5.75 (d, 1H, *J*_{2',3'} 10.5 Hz, H-2'),

5.50 (dd, 1H, *J*_{3',4'} 3.2 Hz, *J*_{4',5'} 1.0 Hz, H-4'), 5.26 (dd, 1H, *J*_{2',3'} 10.5 Hz, *J*_{3',4'} 3.2 Hz, H-3'),

4.41 (ddd, 1H, $J_{5',6'a}$ 7.3 Hz, $J_{5',6'b}$ 6.3 Hz, $J_{4',5'}$ 1.0 Hz, H-5'), 4.16 (dd, 1H, $J_{6'a,6'b}$ 11.6 Hz, $J_{5',6'a}$ 7.3 Hz, H-6'a), 4.07 (dd, 1H, $J_{6'a,6'b}$ 11.6 Hz, $J_{5',6'b}$ 6.3 Hz, H-6'b), 2.20, 2.06, 2.01, 1.95 (4s, 12H, OCOCH₃), 1.88-1.81 (m, 2H, CH₂), 1.79-1.60 (m, 6H, 3 × CH₂), 1.52-1.41 (m, 2H, CH₂); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 170.3 (2), 168.9, 168.8 (CO), 160.3 (C-4), 113.1 (C-2), 100.8 (C-1'), 69.7, 69.3, 67.7, 66.0 (C-2' - C-5'), 61.8 (C-6'), 37.0, 36.0, 24.3, 23.3 (2) (5 × CH₂), 20.6 (2), 20.5 (2) (COCH₃); Calcd for C₂₁H₂₉NO₁₁ (Mol. Wt.: 471.46, Ex. Mass.: 471.17); ESI-MS (positive mode) m/z: 494.164 [M+Na]⁺, 965.336 [2M+Na]⁺.

Fraction III: 0.11 g (25%) of **4**¹⁴ as a white solid.

3.2.5. (1'R)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-2,2-dimethyl-4-imino-1,3-dioxolane (**6a**)

Prepared from **5** (0.50 g, 0.71 mmol) and acetone with AgOTf according to General procedure I (section 3.2). Column chromatography (1:2 EtOAc-hexane than EtOAc) gave two fractions.

Fraction I: 0.18 g (37%) of **6a** as a colourless oil; R_f = 0.51 (1:2 EtOAc-hexane); $[\alpha]_D^{+63}$ (c 0.52, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 8.04-7.24 (m, 20H, ArH), 7.73 (s, 1H, NH), 6.80 (pseudo t, 1H, $J_{2',3'}$ 10.2 Hz, $J_{3',4'}$ 9.7 Hz, H-3'), 5.85 (d, 1H, $J_{2',3'}$ 10.2 Hz, H-2'), 5.76 (pseudo t, 1H, $J_{4',5'}$ 9.9 Hz, $J_{3',4'}$ 9.7 Hz, H-4'), 5.13 (ddd, 1H, $J_{4',5'}$ 9.9 Hz, $J_{5',6'b}$ 4.5 Hz, $J_{5',6'a}$ 1.2 Hz, H-5'), 4.63 (dd, 1H, $J_{6'a,6'b}$ 12.0 Hz, $J_{5',6'a}$ 1.2 Hz, H-6'a), 4.47 (dd, 1H, $J_{6'a,6'b}$ 12.0 Hz, $J_{5',6'b}$ 4.5 Hz, H-6'b), 1.61, 1.29 (2s, 6H, CH₃); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 166.0, 165.4, 165.3, 164.8 (CO), 160.5 (C-4, ³J_{H-2',C-4} = ~5.4 Hz, from HSQMBC at 125 MHz), 112.8 (C-2), 100.3 (C-1'), 70.8, 70.7, 70.5, 69.4 (C-2' - C-5'), 63.1 (C-6'), 27.6, 26.7 (CH₃); Calcd for C₃₈H₃₃NO₁₁ (Mol. Wt.: 679.67, Ex. Mass.: 679.21); ESI-MS (positive mode) m/z: 702.190 [M+Na]⁺, 1381.399 [2M+Na]⁺.

Fraction II: 0.21 g (46%) of **7**³² as a white solid.

3.2.6. (1'R)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-2,2-diethyl-4-imino-1,3-dioxolane (6c)

Prepared from **5** (0.50 g, 0.71 mmol) and pentan-3-one with AgOTf according to General procedure I (section 3.2). Column chromatography (1:2 EtOAc-hexane than EtOAc) gave two fractions.

Fraction I: 0.23 g (46 %) of **6c** as a white foam; $R_f = 0.49$ (1:2 EtOAc-hexane); $[\alpha]_D +60$ (c 0.40, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 8.05-7.20 (m, 20H, ArH), 7.71 (s, 1H, NH), 6.82 (pseudo t, 1H, $J_{2',3'}$ 10.2 Hz, $J_{3',4'}$ 9.8 Hz, H-3'), 5.92 (d, 1H, $J_{2',3'}$ 10.2 Hz, H-2'), 5.76 (pseudo t, 1H, $J_{3',4'}$ 9.8 Hz, $J_{4',5'}$ 9.7 Hz, H-4'), 5.13 (ddd, 1H, $J_{4',5'}$ 9.7 Hz, $J_{5',6'b}$ 5.6 Hz, $J_{5',6'a}$ 2.2 Hz, H-5'), 4.64 (dd, 1H, $J_{6'a,6'b}$ 12.0 Hz, $J_{5',6'a}$ 2.2 Hz, H-6'a), 4.50 (dd, 1H, $J_{6'a,6'b}$ 12.0 Hz, $J_{5',6'b}$ 5.6 Hz, H-6'b), 1.87 (q, 2H, J 7.2 Hz, CH₂CH₃), 1.57 (q, 2H, J 7.4 Hz, CH₂CH₃), 0.90 (t, 3H, J 7.4 Hz, CH₂CH₃), 0.63 (t, 3H, J 7.4 Hz, CH₂CH₃); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 165.9, 165.4 (2), 164.8 (CO), 160.6 (C-4, ³ $J_{H-2',C-4} \approx 4.9$ Hz), 116.6 (C-2), 99.9 (C-1'), 70.9, 70.7, 70.5, 69.5 (C-2' - C-5'), 63.0 (C-6'), 31.2, 29.1 (CH₂CH₃), 7.8, 6.6 (CH₂CH₃); Calcd for C₄₀H₃₇NO₁₁ (Mol. Wt.: 707.72, Ex. Mass.: 707.24); ESI-MS (positive mode) m/z : 730.223 [M+Na]⁺, 1437.468 [2M+Na]⁺.

Fraction II: 0.16 g (35%) of **7**³² as a white solid.

3.2.7. (1'R)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-4-imino-1,3-dioxolane-spiro-[2,1'']-cyclopentane (6d)

Prepared from **5** (0.50 g, 0.71 mmol) and cyclopentanone with Ag₂CO₃ according to General procedure I (section 3.2). Column chromatography (1:2 EtOAc-hexane than EtOAc) gave two fractions.

Fraction I: 0.28 g (56 %) of **6d** as a white foam; $R_f = 0.55$ (1:2 EtOAc-hexane); $[\alpha]_D +62$ (c 0.46, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 8.05-7.22 (m, 20H, ArH), 7.75 (s, 1H, NH), 6.82 (pseudo t, 1H, $J_{2',3'}$ 10.2 Hz, $J_{3',4'}$ 9.8 Hz, H-3'), 5.87 (d, 1H, $J_{2',3'}$ 10.2 Hz, H-2'), 5.79 (pseudo t, 1H, $J_{4',5'}$ 9.9 Hz, $J_{3',4'}$ 9.8 Hz, H-4'), 5.12 (ddd, 1H, $J_{4',5'}$ 9.9 Hz, $J_{5',6'b}$ 4.6 Hz, $J_{5',6'a}$ 2.8 Hz, H-5'), 4.63 (dd, 1H, $J_{6'a,6'b}$ 12.1 Hz, $J_{5',6'a}$ 2.8 Hz, H-6'a), 4.49 (dd, 1H, $J_{6'a,6'b}$ 12.1 Hz, $J_{5',6'b}$ 4.6 Hz, H-6'b), 2.15-2.07 (m, 2H, CH₂), 1.91-1.86 (m, 2H, CH₂), 1.75-1.54 (m, 4H, 2 × CH₂); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 165.9, 165.3, 165.2, 164.8 (CO), 160.3 (C-4, $^3J_{H-2',C-4} \sim 4.9$ Hz), 122.2 (C-2), 99.9 (C-1'), 70.8, 70.6, 70.5, 69.4 (C-2' - C-5'), 62.9 (C-6'), 38.0, 36.3, 23.3, 22.4 (4 × CH₂); Calcd for C₄₀H₃₅NO₁₁ (Mol. Wt.: 705.71, Ex. Mass.: 705.22); ESI-MS (positive mode) m/z: 728.207 [M+Na]⁺, 1433.434 [2M+Na]⁺

Fraction II: 0.08 g (18%) of **7**³² as a white solid.

3.2.8. (1'R)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-4-imino-1,3-dioxolane-spiro-[2,1'']-cyclohexane (6e)

Prepared from **5** (0.50 g, 0.71 mmol) and cyclohexanone with AgOTf according to General procedure I (section 3.2). Column chromatography (1:2 EtOAc-hexane than EtOAc) gave two fractions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Fraction I: 0.14 g (28%) of **6e** as a white foam; $R_f = 0.61$ (1:2 EtOAc-hexane than EtOAc); $[\alpha]_D^{+53}$ (c 0.40, CHCl_3); $^1\text{H NMR}$ (CDCl_3 , 360 MHz): δ (ppm) 8.04-7.24 (m, 20H, ArH), 7.75 (s, 1H, NH), 6.82 (pseudo t, 1H, $J_{2',3'} 10.2$ Hz, $J_{3',4'} 9.9$ Hz, H-3'), 5.87 (d, 1H, $J_{2',3'} 10.2$ Hz, H-2'), 5.77 (pseudo t, 1H, $J_{3',4'} 9.9$ Hz, $J_{4',5'} 9.7$ Hz, H-4'), 5.14 (ddd, 1H, $J_{4',5'} 9.7$ Hz, $J_{5',6'a} 5.0$ Hz, $J_{5',6'a} 2.4$ Hz, H-5'), 4.61 (dd, 1H, $J_{6'a,6'b} 12.2$ Hz, $J_{5',6'a} 2.4$ Hz, H-6'a), 4.49 (dd, 1H, $J_{6'a,6'b} 12.2$ Hz, $J_{5',6'b} 5.0$ Hz, H-6'b), 1.86-1.83 (m, 2H, CH_2), 1.55-1.26 (m, 8H, $4 \times \text{CH}_2$); $^{13}\text{C NMR}$ (CDCl_3 , 90 MHz): δ (ppm) 165.9, 165.3, 165.2, 164.8 (CO), 160.4 (C-4, $^3J_{\text{H-}2',\text{C-}4} \approx 5.0$ Hz), 113.5 (C-2), 99.8 (C-1'), 70.7 (2), 70.5, 69.5 (C-2' - C-5'), 63.0 (C-6'), 37.0, 36.0, 24.1, 22.9, 22.8 ($5 \times \text{CH}_2$); Calcd for $\text{C}_{41}\text{H}_{37}\text{NO}_{11}$ (Mol. Wt.: 719.73, Ex. Mass.: 719.24); ESI-MS (positive mode) m/z : 742.224 $[\text{M}+\text{Na}]^+$, 1461.462 $[2\text{M}+\text{Na}]^+$

Fraction II: 0.16 g (35%) of **7³²** as a white solid.

3.3. General procedure II for the preparation of *O*-perbenzoylated 1',5'-anhydro-D-glucitol-spiro-[1',5]-2,2-disubstituted-oxazolidin-4-ones **8**

Ulosonamide **7³²** was dissolved in a ketone or in a mixture of dry THF or toluene and 5 equiv of a ketone, then TfOH (1 equiv) was added. The mixture was stirred at reflux temp until TLC (9:1 CHCl_3 -acetone) showed complete transformation of the starting material. Then the mixture was diluted with chloroform, washed with satd aq NaHCO_3 , and with water, dried, and the solvent was evaporated. The remaining syrup was purified by column chromatography (18:1 CHCl_3 -acetone).

3.3.1. (1'S)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-2,2-dimethyl-oxazolidin-4-one (8a)

Prepared from **7** (0.1 g, 0.15 mmol) and acetone (5 ml) according to General procedure II (section 3.3) to give 0.09 g (89 %) of **8a** as a white solid. Mp.: 104-107°C; R_f = 0.74 (9:1 CHCl₃-acetone); $[\alpha]_D^{25} +45$ (c 0.40, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 8.70 (s, 1H, NH), 7.99-7.20 (m, 20H, ArH), 6.09 (t, 1H, $J_{2',3'}$ 9.8 Hz, $J_{3',4'}$ 9.8 Hz, H-3'), 5.96 (d, 1H, $J_{2',3'}$ 9.8 Hz, H-2'), 5.73 (t, 1H, $J_{4',5'}$ 9.8 Hz, $J_{3',4'}$ 9.8 Hz, H-4'), 4.66 (ddd, 1H, $J_{4',5'}$ 9.8 Hz, $J_{5',6'b}$ 5.5 Hz, $J_{5',6'a}$ 2.4 Hz, H-5'), 4.58 (dd, 1H, $J_{6'a,6'b}$ 12.3 Hz, $J_{5',6'a}$ 2.4 Hz, H-6'a), 4.47 (dd, 1H, $J_{6'a,6'b}$ 12.3 Hz, $J_{5',6'b}$ 5.5 Hz, H-6'b), 1.64 (s, 3H, CH₃), 1.57 (s, 3H, CH₃); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 166.0 (C-4), 165.8, 165.7, 165.1, 164.3 (CO), 133.4-128.1 (ArC), 100.5 (C-1'), 92.4 (C-2), 71.8, 70.1, 69.4, 68.3 (C-2' - C-5'), 63.2 (C-6'), 29.5 (CH₃), 28.3 (CH₃); Calcd for C₃₈H₃₃NO₁₁ (Mol. Wt.: 679.67, Ex. Mass.: 679.21); ESI-MS (positive mode) m/z : 702.192 [M+Na]⁺, 1381.402 [2M+Na]⁺.

3.3.2. (1'S,2RS)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-2-ethyl-2-methyl-oxazolidin-4-ones (8b)

Prepared from **7** (0.1 g, 0.15 mmol) and butanone (5 ml) according to General procedure II (section 3.3) to give 0.1 g (92 %) an inseparable mixture of **8b** as a white solid. R_f = 0.58 (9:1 CHCl₃-acetone); $[\alpha]_D^{25} +22$ (c 0.42, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 8.89 (s, 1H, NH), 8.05-7.24 (m, 20H, ArH), 6.10, 6.09 (t, 1H, $J_{2',3'}$ 10.4 Hz, $J_{3',4'}$ 9.8 Hz, H-3'), 5.99, 5.97 (d, 1H, $J_{2',3'}$ 10.4 Hz, H-2'), 5.72, 5.71 (t, 1H, $J_{4',5'}$ 9.8 Hz, $J_{3',4'}$ 9.8 Hz, H-4'), 4.63 (ddd, 1H, $J_{4',5'}$ 9.8 Hz, $J_{5',6'b}$ 5.5 Hz, $J_{5',6'a}$ 2.4 Hz, H-5'), 4.59 (dd, 1H, $J_{6'a,6'b}$ 12.3 Hz, $J_{5',6'a}$ 2.4 Hz, H-6'a), 4.45 (dd, 1H, $J_{6'a,6'b}$ 12.3 Hz, $J_{5',6'b}$ 5.5 Hz, H-6'b), 1.89, 1.85 (2q, 2H, J 7.5

1 Hz, CH₂), 1.65, 1.56 (2s, 3H, CH₃), 0.98, 0.95 (2t, 3H, *J* 7.5 Hz CH₃); ¹³C NMR (CDCl₃, 90
2 MHz): δ (ppm) 166.4, 166.1 (C-4), 165.9, 165.6, 165.1, 164.3 (CO), 133.4-128.1 (ArC), 100.3
3 (C-1'), 94.9, 94.5 (C-2), 71.7, 70.3, 69.9, 69.4, 69.3, 68.6, 68.4 (C-2' - C-5'), 63.2 (C-6'),
4
5 34.9, 33.7 (CH₂), 27.3, 26.1 (CH₃), 8.0, 7.5 (CH₃); Calcd for C₃₉H₃₅NO₁₁ (Mol. Wt.: 693.70,
6
7 Ex. Mass.: 693.22); ESI-MS (positive mode) *m/z*: 716.209 [M+Na]⁺, 1409.435 [2M+Na]⁺.
8
9

10
11
12
13
14 **3.3.3. (1'S)-2',3',4',6'-Tetra-*O*-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-2,2-diethyl-**
15 **oxazolidin-4-one (8c)**
16
17

18
19
20
21
22 Prepared from **7** (0.1 g, 0.15 mmol) and pentan-3-one (82 μl, 0.75 mmol) in dry THF (5
23 ml) according to General procedure II (section 3.3) to give 0.07 g (69 %) of **8c** as a white
24 solid. Mp.: 101-103°C; *R*_f = 0.66 (9:1 CHCl₃-acetone); [α]_D +27 (c 0.32, CHCl₃); ¹H NMR
25 (CDCl₃, 360 MHz): δ (ppm) 9.07 (s, 1H, NH), 8.00-7.17 (m, 20H, ArH), 6.10 (t, 1H, *J*_{2',3'} 9.8
26 Hz, *J*_{3',4'} 9.8 Hz, H-3'), 6.00 (d, 1H, *J*_{2',3'} 9.8 Hz, H-2'), 5.70 (t, 1H, *J*_{4',5'} 9.8 Hz, *J*_{3',4'} 9.8 Hz,
27 H-4'), 4.64 (ddd, 1H, *J*_{4',5'} 9.8 Hz, *J*_{5',6'b} 6.7 Hz, *J*_{5',6'a} 2.4 Hz, H-5'), 4.60 (dd, 1H, *J*_{6'a,6'b} 12.3
28 Hz, *J*_{5',6'a} 2.4 Hz, H-6'a), 4.45 (dd, 1H, *J*_{6'a,6'b} 12.3 Hz, *J*_{5',6'b} 6.7 Hz, H-6'b), 1.86, 1.75 (2q,
29 4H, *J* 7.0 Hz, CH₂), 0.89, 0.85 (2t, 6H, *J* 7.0 Hz, CH₃); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm)
30 166.6 (C-4), 165.9, 165.6, 165.1, 164.3 (CO), 133.4-128.1 (ArC), 100.2 (C-1'), 97.1 (C-2),
31 71.6, 70.2, 69.4, 68.6 (C-2' - C-5'), 63.3 (C-6'), 32.2 (CH₂), 30.9 (CH₂), 7.8 (CH₃), 7.3 (CH₃);
32
33 Calcd for C₄₀H₃₇NO₁₁ (Mol. Wt.: 707.72, Ex. Mass.: 707.24); ESI-MS (positive mode) *m/z*:
34
35 730.225 [M+Na]⁺, 1437.464 [2M+Na]⁺.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3.3.4. (1'S)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-4-oxo-oxazolidine-spiro-[2,1'']-cyclopentane (8d)

Prepared from **7** (0.1 g, 0.15 mmol) and cyclopentanone (70 μ l, 0.75 mmol) in dry THF (5 ml) according to General procedure II (section 3.3) to give 0.08 g (78 %) of **8d** as a white solid. Mp.: 180-182°C; R_f = 0.72 (9:1 CHCl₃–acetone); $[\alpha]_D$ +49 (c 0.62, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 8.84 (s, 1H, NH), 8.04-7.28 (m, 20H, ArH), 6.08 (t, 1H, $J_{2',3'}$ 9.8 Hz, $J_{3',4'}$ 9.8 Hz, H-3'), 5.97 (d, 1H, $J_{2',3'}$ 9.8 Hz, H-2'), 5.73 (t, 1H, $J_{4',5'}$ 9.2 Hz, $J_{3',4'}$ 9.8 Hz, H-4'), 4.63 (ddd, 1H, $J_{4',5'}$ 9.2 Hz, $J_{5',6'b}$ 6.1 Hz, $J_{5',6'a}$ 3.1 Hz, H-5'), 4.58 (dd, 1H, $J_{6'a,6'b}$ 12.3 Hz, $J_{5',6'a}$ 3.1 Hz, H-6'a), 4.47 (dd, 1H, $J_{6'a,6'b}$ 12.3 Hz, $J_{5',6'b}$ 6.1 Hz, H-6'b), 2.08-1.71 (m, 8H, 4 \times CH₂); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 166.1 (C-4), 165.9, 165.7, 165.1, 164.3 (CO), 133.4-128.1 (ArC), 100.7 (C-1'), 100.1 (C-2), 71.8, 70.2, 69.4, 68.3 (C-2' - C-5'), 63.2 (C-6'), 39.9, 37.7, 23.1, 22.6 (CH₂); Calcd for C₄₀H₃₅NO₁₁ (Mol. Wt.: 705.71, Ex. Mass.: 705.22); ESI-MS (positive mode) m/z: 728.210 [M+Na]⁺, 1433.435 [2M+Na]⁺.

3.3.5. (1'S)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-4-oxo-oxazolidine-spiro-[2,1'']-cyclohexane (8e)

Prepared from **7** (0.1 g, 0.15 mmol) and cyclohexanone (80 μ l, 0.75 mmol) in dry toluene (5 ml) according to General procedure II (section 3.3) to give 0.07 g (69 %) of **8e** as a white solid. Mp.: 178-181°C; R_f = 0.78 (9:1 CHCl₃–acetone); $[\alpha]_D$ +52 (c 0.46, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 9.00 (s, 1H, NH), 8.12-7.30 (m, 20H, ArH), 6.10 (t, 1H, $J_{2',3'}$ 9.8 Hz, $J_{3',4'}$ 9.8 Hz, H-3'), 6.00 (d, 1H, $J_{2',3'}$ 9.8 Hz, H-2'), 5.71 (t, 1H, $J_{4',5'}$ 9.8 Hz, $J_{3',4'}$ 9.8 Hz, H-4'), 4.69 (ddd, 1H, $J_{4',5'}$ 9.8 Hz, $J_{5',6'b}$ 6.7 Hz, $J_{5',6'a}$ 3.1 Hz, H-5'), 4.63 (dd, 1H, $J_{6'a,6'b}$ 12.3 Hz, $J_{5',6'a}$ 3.1 Hz, H-6'a), 4.45 (dd, 1H, $J_{6'a,6'b}$ 12.3 Hz, $J_{5',6'b}$ 6.7 Hz, H-6'b), 1.92-1.32 (m,

10H, 5 × CH₂); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 166.4 (C-4, ³J_{H-2',C-4} = 2.5 Hz from HSQMBC at 125 MHz), 166.0, 165.7, 165.2, 164.3 (C'O), 133.4-128.2 (ArC), 100.1 (C-1'), 93.5 (C-2), 71.8, 70.3, 69.4, 68.3 (C-2' - C-5'), 63.3 (C-6'), 39.0, 37.6, 24.3, 22.9, 22.6 (CH₂); Calcd for C₄₁H₃₇NO₁₁ (Mol. Wt.: 719.73, Ex. Mass.: 719.24); ESI-MS (positive mode) m/z: 742.222 [M+Na]⁺, 1462.462 [2M+Na]⁺.

3.3.6. (1'S)-2',3',4',6'-Tetra-O-benzoyl-1',5'-anhydro-D-glucitol-spiro-[1',5]-4-oxo-oxazolidine-spiro-[2,1'']-cycloheptane (8f)

Prepared from **7** (0.1 g, 0.15 mmol) and cycloheptanone (81 μl, 0.75 mmol) in dry toluene (5 ml) according to General procedure II (section 3.3) to give 0.08 g (71 %) of **8f** as a white solid. Mp.: 124-126°C; R_f = 0.55 (9:1 CHCl₃-acetone); [α]_D +59 (c 0.36, CHCl₃); ¹H NMR (CDCl₃, 360 MHz): δ (ppm) 9.31 (s, 1H, NH), 8.00-7.18 (m, 20H, ArH), 6.08 (t, 1H, J_{2',3'} 9.8 Hz, J_{3',4'} 9.8 Hz, H-3'), 5.98 (d, 1H, J_{2',3'} 9.8 Hz, H-2'), 5.70 (t, 1H, J_{4',5'} 9.8 Hz, J_{3',4'} 9.8 Hz, H-4'), 4.66 (ddd, 1H, J_{4',5'} 9.8 Hz, J_{5',6'b} 6.8 Hz, J_{5',6'a} 3.1 Hz, H-5'), 4.61 (dd, 1H, J_{6'a,6'b} 12.3 Hz, J_{5',6'a} 3.1 Hz, H-6'a), 4.44 (dd, 1H, J_{6'a,6'b} 12.3 Hz, J_{5',6'b} 6.8 Hz, H-6'b), 2.12-1.45 (m, 12H, 6 × CH₂); ¹³C NMR (CDCl₃, 90 MHz): δ (ppm) 166.1 (C-4), 165.9, 165.6, 165.1, 164.2 (CO), 133.3-128.1 (ArC), 100.1 (C-1'), 97.2 (C-2), 71.8, 70.1, 69.4, 68.3 (C-2' - C-5'), 63.2 (C-6'), 42.4, 41.2, 28.2, 28.1, 21.4, 21.1 (CH₂); Calcd for C₄₂H₃₉NO₁₁ (Mol. Wt.: 733.76, Ex. Mass.: 733.25); ESI-MS (positive mode) m/z: 756.240 [M+Na]⁺, 1490.498 [2M+Na]⁺.

3.4. General procedure III for the removal of *O*-acyl protecting groups

An *O*-acylated compound was dissolved in the minimum volume of abs MeOH and a few drops of NaOMe in MeOH (~1 M) were added. The mixture was stirred at rt until TLC (9:1 CHCl₃-MeOH) showed complete transformation of the starting material. It was then neutralized with a cation exchange resin Amberlyst 15 (H⁺ form). Filtration and solvent removal left a syrup which was purified by column chromatography (CHCl₃-MeOH).

3.4.1. (1'*S*)-1',5'-Anhydro-D-glucitol-spiro-[1',5]-2,2-dimethyl-oxazolidin-4-one (9a)

Prepared from **8a** (0.14 g, 0.20 mmol) according to General procedure III (section 3.4) to give 0.05 g (94 %) of **9a** as a white solid. Mp.: 97-99°C; *R*_f = 0.3 (8:2 CHCl₃-MeOH); [α]_D +50 (c 0.28, MeOH); ¹H NMR (D₂O 360 MHz): δ (ppm) 3.90-3.67 (m, 5H, H-2', H-3' or H-4', H-5', H-6'ab), 3.51 (pseudo t, 1H, *J*₌ 8.7 Hz, 7.7 Hz, H-3' or H-4'), 1.61 (s, 3H, CH₃), 1.58 (s, 3H, CH₃); ¹³C NMR (D₂O, 90 MHz): δ (ppm) 168.4 (C-4), 102.3 (C-1'), 92.6 (C-2), 74.1, 73.6, 69.7, 69.4 (C-2' - C-5'), 60.6 (C-6'), 28.6 (CH₃), 27.1 (CH₃); Calcd for C₁₀H₁₇NO₇ (Mol. Wt.: 263.24, Ex. Mass.: 263.10); ESI-MS (positive mode) *m/z*: 286.088 [M+Na]⁺, 549.192 [2M+Na]⁺, 812.290 [3M+Na]⁺.

3.4.2. (1'*S*,2*RS*)-1',5'-Anhydro-D-glucitol-spiro-[1',5]-2-ethyl-2-methyl-oxazolidin-4-ones (9b)

Prepared from **8b** (0.17 g, 0.25 mmol) according to General procedure III (section 3.4) to give 0.06 g (96 %) of **9b** as a white solid. *R*_f = 0.3 (8:2 CHCl₃-MeOH); [α]_D +53 (c 0.46, MeOH); ¹H NMR (D₂O 360 MHz): δ (ppm) 3.82-3.44 (m, 6H, H-2', H-3', H-4', H-5', H-

6'ab), 1.79-1.75 (m, 2H, CH₂), 1.51, 1.48 (2s, 3H, CH₃), 0.90, 0.86 (2t, 3H, *J* 7.5 Hz CH₃);
¹³C NMR (D₂O, 90 MHz): δ (ppm) 168.9, 168.6 (C-4), 102.2, 101.9 (C-1'), 95.2, 94.7 (C-2),
 74.3, 73.9, 73.5, 69.8, 69.7, 69.5, 69.3 (C-2' - C-5'), 60.5 (C-6'), 34.1, 33.0 (CH₂), 26.4, 25.3
 (CH₃), 7.3, 6.9 (CH₃); Calcd for: C₁₁H₁₉NO₇ (Mol. Wt.: 277.27, Ex. Mass.: 277.12); ESI-MS
 (positive mode) m/z: 300.104 [M+Na]⁺, 577.225 [2M+Na]⁺, 854.342 [3M+Na]⁺.

3.4.3. (1'S)-1',5'-Anhydro-D-glucitol-spiro-[1',5]-2,2-diethyl-oxazolidin-4-one (9c)

Prepared from **8c** (0.14 g, 0.20 mmol) according to General procedure III (section 3.4) to
 give 0.05 g (91 %) of **9c** as a white solid. Mp.: 70-72°C; *R_f* = 0.3 (8:2 CHCl₃-MeOH); [α]_D
 +48 (c 0.44, MeOH); ¹H NMR (D₂O 360 MHz): δ (ppm) 3.82-3.61 (m, 5H, H-2', H-3' or H-
 4', H-5', H-6'ab), 3.44 (t, 1H, *J* = 7.6 Hz, 7.6 Hz, H-3' or H-4') 1.82-1.75 (m, 4H, 2 × CH₂),
 0.89, 0.87 (2t, 6H, *J* 7.5 Hz, 2 × CH₃); ¹³C NMR (D₂O, 90 MHz): δ (ppm) 168.9, (C-4), 101.9
 (C-1'), 97.3 (C-2), 74.1, 73.5, 69.9, 69.4, (C-2' - C-5'), 60.5 (C-6'), 31.4, 30.7 (CH₂), 7.1, 6.9
 (CH₃); Calcd for C₁₂H₂₁NO₇ (Mol. Wt.: 291.30, Ex. Mass.: 291.13); ESI-MS (positive mode)
 m/z: 314.120 [M+Na]⁺, 605.255 [2M+Na]⁺, 896.387 [3M+Na]⁺.

3.4.4. (1'S)-1',5'-Anhydro-D-glucitol-spiro-[1',5]-oxazolidin-4-one-spiro-[2,1']-cyclopentane (9d)

Prepared from **8d** (0.19 g, 0.27 mmol) according to General procedure III (section 3.4) to
 give 0.07 g (91 %) of **9d** as a white solid. Mp.: 112-115°C; *R_f* = 0.3 (8:2 CHCl₃-MeOH); [α]_D
 +46 (c 0.43, MeOH); ¹H NMR (D₂O 360 MHz): δ (ppm) 3.82-3.62 (m, 5H, H-2', H-3' or H-
 4', H-5', H-6'ab), 3.44 (pseudo t, 1H, *J* = 7.8 Hz, 7.3 Hz, H-3' or H-4') 1.94-1.69 (m, 8H, 4 ×
 CH₂); ¹³C NMR (D₂O, 90 MHz): δ (ppm) 168.6, (C-4), 101.9, 101.8 (C-1', C-2), 74.2, 73.6,

69.6, 69.3, (C-2' - C-5'), 60.5 (C-6'), 39.3, 36.9 22.8, 22.2 (CH₂); Calcd for C₁₂H₁₉NO₇ (Mol. Wt.: 289.28, Ex. Mass.: 289.12); ESI-MS (positive mode) m/z: 312.104 [M+Na]⁺, 601.222 [2M+Na]⁺, 890.335 [3M+Na]⁺.

3.4.5. (1'S)-1',5'-Anhydro-D-glucitol-spiro-[1',5]-oxazolidin-4-one-spiro-[2,1'']-cyclohexane (9e)

Prepared from **8e** (0.18 g, 0.25 mmol) according to General procedure III (section 3.4) to give 0.07 g (96 %) of **9e** as a white solid. Mp.: 123-126°C; *R_f* = 0.3 (8:2 CHCl₃-MeOH); [α]_D +42 (c 0.32, MeOH); ¹H NMR (D₂O 360 MHz): δ (ppm) 3.86-3.62 (m, 5H, H-2', H-3' or H-4', H-5', H-6'ab), 3.48 (pseudo t, 1H, *J*₌ 8.9 Hz, 7.9 Hz, H-3' or H-4') 1.87-1.37 (m, 10H, 5 × CH₂); ¹³C NMR (D₂O, 90 MHz): δ (ppm) 168.6, (C-4), 101.8 (C-1'), 93.6 (C-2), 74.3, 73.6, 69.7, 69.4, (C-2' - C-5'), 60.6 (C-6'), 38.5, 36.6, 23.9, 22.6, 22.2 (CH₂); Calcd for C₁₃H₂₁NO₇ (Mol. Wt.: 303.31, Ex. Mass.: 303.13); ESI-MS (positive mode) m/z: 326.120 [M+Na]⁺, 629.253 [2M+Na]⁺, 932.384 [3M+Na]⁺.

3.4.6. (1'S)-1',5'-Anhydro-D-glucitol-spiro-[1',5]-oxazolidin-4-one-spiro-[2,1'']-cycloheptane (9f)

Prepared from **8f** (0.19 g, 0.26 mmol) according to General procedure III (section 3.4) to give 0.06 g (77 %) of **9f** as a white solid. Mp.: 116-119°C; *R_f* = 0.3 (8:2 CHCl₃-MeOH); [α]_D +48 (c 0.30, MeOH); ¹H NMR (D₂O 360 MHz): δ (ppm) 3.88-3.67 (m, 5H, H-2', H-3' or H-4', H-5', H-6'ab), 3.50 (pseudo t, 1H, *J*₌ 7.4 Hz, 7.2 Hz, H-3' or H-4') 2.14-1.52 (m, 12H, 6 × CH₂); ¹³C NMR (D₂O, 90 MHz): δ (ppm) 168.4, (C-4), 101.9 (C-1'), 97.4 (C-2), 74.2, 73.6, 69.8, 69.4, (C-2' - C-5'), 60.6 (C-6'), 41.8, 40.6, 28.3, 28.2, 21.1, 21.0 (CH₂); Calcd for

C₁₄H₂₃NO₇ (Mol. Wt.: 317.33, Ex. Mass.: 317.15); ESI-MS (positive mode) m/z: 340.136

[M+Na]⁺, 657.287 [2M+Na]⁺, 974.436 [3M+Na]⁺.

Acknowledgement

This work was supported by the Hungarian Scientific Research Fund (OTKA 32124, 109450). T. Docsa is thanked for the enzyme assays.

References

1. Pradhan, R.; Patra, M.; Behera, A. K.; Mishra, B. K.; Behera, R. K. *Tetrahedron* **2006**, *62*, 779-828.
2. Kotha, S.; Deb, A. C.; Lahiri, K.; Manivannan, E. *Synthesis* **2009**, 165-+.
3. Rios, R. *Chem. Soc. Rev.* **2012**, *41*, 1060-1074.
4. Campbell, W. C. *Curr. Pharm. Biotechnol.* **2012**, *13*, 853-865.
5. Sperry, J.; Wilson, Z. E.; Rathwell, D. C. K.; Brimble, M. A. *Nat. Prod. Rep.* **2010**, *27*, 1117-1137.
6. Somsák, L.; Bokor, É.; Czifrák, K.; Juhász, L.; Tóth, M. In *Topics in the Prevention, Treatment and Complications of Type 2 Diabetes*; Zimering, M. B. Ed.; InTech Open Access Publisher: Rijeka, 2011; pp. 103-126.
7. Duke, S. O.; Dayan, F. E. *Toxins* **2011**, *3*, 1038-1064.
8. Benlifa, M.; De Kiss, M.; Garcia-Moreno, M. I.; Mellet, C. O.; Gueyard, D.; Wadouachi, A. *Tetrahedron: Asymm.* **2009**, *20*, 1817-1823.
9. Pal, A. P. J.; Vankar, Y. D. *Tetrahedron Lett.* **2010**, *51*, 2519-2524.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
10. Pal, A. P. J.; Gupta, P.; Reddy, Y. S.; Vankar, Y. D. *Eur. J. Org. Chem.* **2010**, 6957-6966.
 11. Somsák, L. *Compt. Rend. Chimie* **2011**, *14*, 211-223.
 12. Soengas, R. G.; Silva, S. *Mini-Rev. Med. Chem.* **2012**, *12*, 1485-1496.
 13. Somsák, L.; Czifrák, K. *Carbohydr. Chem.* **2013**, *39*, 1-37.
 14. Ósz, E.; Sós, E.; Somsák, L.; Szilágyi, L.; Dinya, Z. *Tetrahedron* **1997**, *53*, 5813-5824.
 15. Somsák, L.; Kovács, L.; Tóth, M.; Ósz, E.; Szilágyi, L.; Györgydeák, Z.; Dinya, Z.; Docsa, T.; Tóth, B.; Gergely, P. *J. Med. Chem.* **2001**, *44*, 2843-2848.
 16. Czifrák, K.; Deák, S.; Páhi, A.; Chrysina, E. D.; Alexacou, K.-M.; Oikonomakos, N. G.; Somsák, L. In *25th International Carbohydrate Symposium*: Tokyo, Japan, Aug 1-6, 2010. A-02-005, 2010.
 17. Czifrák, K.; Gyóllai, V.; Kövér, K. E.; Somsák, L. *Carbohydr. Res.* **2011**, *346*, 2104-2112.
 18. Ósz, E.; Szilágyi, L.; Somsák, L.; Bényei, A. *Tetrahedron* **1999**, *55*, 2419-2430.
 19. Somsák, L.; Kovács, L.; Gyóllai, V.; Ósz, E. *Chem. Commun.* **1999**, 591-592.
 20. Koto, S.; Inada, S.; Narita, T.; Morishima, N.; Zen, S. *Bull. Chem. Soc. Jpn.* **1982**, *55*, 3665-3666.
 21. Tietze, L. F.; Fischer, R.; Logers, M.; Beller, M. *Carbohydr. Res.* **1989**, *194*, 155-162.
 22. Tietze, L. F.; Beller, M. *Liebigs Ann.* **1990**, 587-591.
 23. Aloui, M.; Fairbanks, A. J. *Chem. Commun.* **2001**, 1406-1407.
 24. Buchan, Z. A.; Bader, S. J.; Montgomery, J. *Angew. Chem. Int. Edit.* **2009**, *48*, 4840-4844.
 25. Li, J. J. *Name Reactions - A Collection of Detailed Reaction Mechanisms*, 3rd ed.; Springer: Berlin, Heidelberg, 2006.


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
26. Williamson, R. T.; Marquez, B. L.; Gerwick, W. H.; Kövér, K. E. *Magn. Reson. Chem.* **2000**, *38*, 265-273.
27. Kövér, K. E.; Batta, G.; Fehér, K. *J. Magn. Reson.* **2006**, *181*, 89-97.
28. Boros, S.; Kövér, K. E. *Magn. Reson. Chem.* **2011**, *49*, 106-110.
29. Kim, K. S.; Suk, D. H. *Trends Glycosci. Glycotechnol.* **2011**, *23*, 53-66.
30. Sigel, H.; Martin, R. B. *Chem. Rev.* **1982**, *82*, 385-426.
31. Kiss, L.; Somsák, L. *Carbohydr. Res.* **1996**, *291*, 43-52.
32. Somsák, L.; Nagy, V. *Tetrahedron: Asymm.* **2000**, *11*, 1719-1727. Corrigendum 2247.

- Ketone incorporation reactions.
- Preparation of glycopyranosylidene-spiro-(4-imino-1,3-dioxolanes).
- Preparation of glycopyranosylidene-spiro-(oxazolidin-4-ones).

ACCEPTED MANUSCRIPT

**Anomeric Spirocycles by Solvent Incorporation:
Reactions of *O*-Peracetylated (Glyculopyranose and
Glyculopyranosyl Bromide)onamide Derivatives with Ketones**

A. Páhi, K. Czifrák, K. E. Kövér, L. Somsák*



* Corresponding author – Tel.: +3652512900 ext. 22348, Fax: +3652512744, E-mail: somsak.laszlo@science.unideb.hu